Company Information

IPCA LABORATORIES LTD.

NSE : IPCALABBSE : 524494ISIN CODE : INE571A01038Industry : Pharmaceuticals & DrugsHouse : Ipca Laboratories
BSE1238.2540.1 (+3.35 %)
PREV CLOSE ( ) 1198.15
OPEN PRICE ( ) 1200.65
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 65795
TODAY'S LOW / HIGH ( )1200.65 1245.00
52 WK LOW / HIGH ( )670 1264
NSE1237.4032.1 (+2.66 %)
PREV CLOSE( ) 1205.30
OPEN PRICE ( ) 1205.40
BID PRICE (QTY) 1237.40 (675)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 668011
TODAY'S LOW / HIGH( ) 1202.35 1245.00
52 WK LOW / HIGH ( )669.8 1263.95
ChairmanPremchand Godha
Managing DirectorAjit Kumar Jain
Pranay Godha
Company SecretaryHarish P Kamath
Executive DirectorPrashant Godha
Non Executive Independent DirectorAnand T Kusre
Manisha Premnath
Kamal Kishore Seth
Narendra Mairpady
Incorporation Year : 19-10 1949

Registered Office :

Address : 48 , Kandivli Industrial Estate,Kandivli (West), Mumbai,
Maharashtra-400067 .

Phone : 022- 66474444 / 62106050

Email :  investors@ipca.com 

URL : www.ipca.com

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE,MCX

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.